Mucosal Leishmaniasis is Associated with the Leishmania RNA Virus and Inappropriate Cutaneous Leishmaniasis Treatment

Overview

Journal PLoS One

Date 2025 Jan 24

PMID 39854299

Authors

Fredy A Pazmino

Marcela Parra-Munoz

Carlos H Saavedra

Sandra Muvdi-Arenas

Clemencia Ovalle-Bracho

Maria C Echeverry

Affiliations

Soon will be listed here.

Abstract

Background: Mucosal leishmaniasis (ML) is a severe clinical form of leishmaniasis that is characterized by the destruction of the nasal and/or the oral mucosae and appears as a late complication in 5% to 10% of cutaneous leishmaniasis (CL) cases produced by species belonging to Leishmania (Viannia) subgenus. Some strains of Leishmania spp. carry an RNA virus known as Leishmania RNA virus (LRV) that may contribute to the appearance of ML.

Methods: To examine the role of LRV type 1 (LRV1) as a risk factor associated with ML, a retrospective case-control study involving 103 patients was conducted. Cases were defined as patients with ML (n = 33), and controls corresponded to patients with CL and without mucosal lesions (n = 70). Clinical data were recorded from the patient's medical records. Cryopreserved biopsies were used to detect LRV1 and identify Leishmania species.

Results: The frequency of LRV1 in the 103 patients was 16.5% (95% CI,10.4-25.12) being higher in samples from cases [33.33% (95% CI,18.89-51.76) than from controls [8.57% (95% CI, 3.82-18.10)]. L. (V.) braziliensis was identified in 63.6% of cases and 55.7% of the controls. Multivariate logistic regression indicated that infection with Leishmania spp. carrying LRV1 (OR = 6.30; 95% CI,1.52-26.10, p = 0.011) acts as risk factors for ML occurrence, while the completed treatment for the cutaneous event decreases the risk of ML (OR = 0.039; 95% CI, 0.01-0.12, p < 0.0001).

Conclusions: Our data support the association between LRV1 and ML occurrence and emphasize the effect of completed treatment for CL in preventing ML.

References

Carvalho E, Johnson W, Barreto E, Marsden P, Costa J, Reed S . Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol. 1985; 135(6):4144-8. View

Jones T, Johnson Jr W, BARRETTO A, Lago E, Badaro R, Cerf B . Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis. 1987; 156(1):73-83. DOI: 10.1093/infdis/156.1.73. View

Tarr P, Aline Jr R, Smiley B, Scholler J, Keithly J, Stuart K . LR1: a candidate RNA virus of Leishmania. Proc Natl Acad Sci U S A. 1988; 85(24):9572-5. PMC: 282800. DOI: 10.1073/pnas.85.24.9572. View

Strazzulla A, Cocuzza S, Pinzone M, Postorino M, Cosentino S, Serra A . Mucosal leishmaniasis: an underestimated presentation of a neglected disease. Biomed Res Int. 2013; 2013:805108. PMC: 3703408. DOI: 10.1155/2013/805108. View

Ramasawmy R, Menezes E, Magalhaes A, Oliveira J, Castellucci L, Almeida R . The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. Infect Genet Evol. 2010; 10(5):607-13. PMC: 2878927. DOI: 10.1016/j.meegid.2010.04.006. View

Gonzalez K, De Leon S, Pineda V, Samudio F, Capitan-Barrios Z, Suarez J . Detection of Leishmania RNA Virus 1 in Leishmania (Viannia) panamensis Isolates, Panama. Emerg Infect Dis. 2023; 29(6):1250-1253. PMC: 10202884. DOI: 10.3201/eid2906.220012. View

Bailey M, Lockwood D . Cutaneous leishmaniasis. Clin Dermatol. 2007; 25(2):203-11. DOI: 10.1016/j.clindermatol.2006.05.008. View

Martinez-Valencia A, Daza-Rivera C, Rosales-Chilama M, Cossio A, Casadiego Rincon E, Desai M . Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017; 11(7):e0005713. PMC: 5526576. DOI: 10.1371/journal.pntd.0005713. View

Cabrera M, Shaw M, Sharples C, Williams H, Castes M, Convit J . Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med. 1995; 182(5):1259-64. PMC: 2192198. DOI: 10.1084/jem.182.5.1259. View

10.

Ito M, Catanhede L, Katsuragawa T, Silva Junior C, Aranha Camargo L, Mattos R . Correlation between presence of Leishmania RNA virus 1 and clinical characteristics of nasal mucosal leishmaniosis. Braz J Otorhinolaryngol. 2015; 81(5):533-40. PMC: 9449032. DOI: 10.1016/j.bjorl.2015.07.014. View

11.

Castellucci L, Menezes E, Oliveira J, Magalhaes A, Guimaraes L, Lessa M . IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis. 2006; 194(4):519-27. DOI: 10.1086/505504. View

12.

Ovalle-Bracho C, Camargo C, Diaz-Toro Y, Parra-Munoz M . [Molecular typing of Leishmania (Leishmania) amazonensis and species of the subgenus Viannia associated with cutaneous and mucosal leishmaniasis in Colombia: A concordance study]. Biomedica. 2018; 38(1):86-95. DOI: 10.7705/biomedica.v38i0.3632. View

12.

Nagasawa K, Matsushima Y, Motoya T, Mizukoshi F, Ueki Y, Sakon N . Genetic Analysis of Human Norovirus Strains in Japan in 2016-2017. Front Microbiol. 2018; 9:1. PMC: 5778136. DOI: 10.3389/fmicb.2018.00001. View

13.

Parra-Munoz M, Aponte S, Ovalle-Bracho C, Saavedra C, Echeverry M . Detection of RNA Virus in Clinical Samples from Cutaneous Leishmaniasis Patients Varies according to the Type of Sample. Am J Trop Med Hyg. 2020; 104(1):233-239. PMC: 7790072. DOI: 10.4269/ajtmh.20-0073. View

14.

Lessa H, Lessa M, Guimaraes L, Lima C, Arruda S, Machado P . A proposed new clinical staging system for patients with mucosal leishmaniasis. Trans R Soc Trop Med Hyg. 2012; 106(6):376-81. PMC: 3360834. DOI: 10.1016/j.trstmh.2012.03.007. View

15.

Guerra J, Prestes S, Silveira H, Coelho L, Gama P, Moura A . Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis. 2011; 5(3):e980. PMC: 3050903. DOI: 10.1371/journal.pntd.0000980. View

16.

Blum J, Lockwood D, Visser L, Harms G, Bailey M, Caumes E . Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health. 2013; 4(3):153-63. DOI: 10.1016/j.inhe.2012.06.004. View

17.

Navas A, Fernandez O, Gallego-Marin C, Castro M, Rosales-Chilama M, Murillo J . Profiles of Local and Systemic Inflammation in the Outcome of Treatment of Human Cutaneous Leishmaniasis Caused by (). Infect Immun. 2019; 88(3). PMC: 7035935. DOI: 10.1128/IAI.00764-19. View

18.

Morais R, Melo M, Goes T, Pessoa E Silva R, de Morais R, Guerra J . Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil. Exp Parasitol. 2022; 240:108338. DOI: 10.1016/j.exppara.2022.108338. View

19.

Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L . Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis. 2008; 46(2):223-31. DOI: 10.1086/524042. View